Navigation Links
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
Date:5/7/2008

sments were completed on specified days at approximately 6 PM (after school and before dinner), 8 PM (dinner through bedtime) and 6 AM (waking time/new dose administration time), which represented 12, 14 and 24 hours after the administration of the dose of INTUNIV, respectively. The data demonstrated significant improvement of ADHD symptoms based on total endpoint CPRS-R scores for all weight adjusted dose groups treated with INTUNIV when compared to placebo for all time periods (at 12 hours, P=<.001; at 14 hours, P<.001; and at 24 hours, P=.003).

A separate analysis of the same phase III studies evaluated the percentage of ADHD patients who responded to weight-adjusted treatment with INTUNIV versus those participants receiving placebo. Using the change in the ADHD-RS-IV total score from baseline to endpoint as the primary efficacy measure, responders were defined as those with a 25 percent reduction in score from baseline to endpoint. Findings from the analysis showed that all groups treated with INTUNIV responded to the medication in a shorter time period than the placebo group (14 days versus 20 days, respectively, P=.001).

In the phase III studies, adverse events (AEs) were reported in 80.7 percent of patients treated with INTUNIV and 71.8 percent of patients treated with placebo. Overall, the AEs were mostly mild to moderate in severity. Adverse reactions that appeared to be dose-related in patients given INTUNIV included upper abdominal pain, constipation, dizziness, dry mouth, hypotension, sedation, and somnolence. Serious AEs reported in these analyses were uncommon and rates were similar between patients treated with INTUNIV and patients treated with placebo (0.6% of the INTUNIV group and 0.7% of placebo group, respectively).

About INTUNIV

INTUNIV, a once-daily formulation of guanfacine, provides a controlled, steady delivery of drug throughout the day with a delivery system that is designed to minimize the fluctuations between p
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
3. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
4. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
5. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
6. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
7. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
8. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
9. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... of the first-quarter 2010 cash dividend of $0.16 per ... 2010 to shareholders of record on January 20, 2010. ... a global manufacturer of components and systems for injectable ... closures and disposable components used in syringe, IV and ...
(Date:12/15/2009)... Ind., Dec. 15 OrthoWorx, the newly formed ... the orthopedics device sector in Kosciusko County, is working ... major cities like Chicago and Cleveland via high-speed rail. ... Warsaw, Indiana: The Orthopedics Capital of the World ... and community growth, BioCrossroads, the statewide initiative ...
(Date:12/15/2009)... -- Ever wonder what something looks like up close ... the Personal Scanning Electron Microscope (PSEM), kicked off its ... in samples to be scanned by one of their ... range of 100nm to 5mm and an imaging resolution ... focus. In addition, ASPEX will not only scan your ...
Breaking Medicine Technology:OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 2OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 3ASPEX Kicks Off Free 'Send Us Your Sample' Microscopy Campaign 2Four Michigan Companies Receive 24200 000 From Ann Arbor SPARKs Microloan Program 14875 1Four Michigan Companies Receive 24200 000 From Ann Arbor SPARKs Microloan Program 14875 2A New Weapon In The Battle Of The Bra Bulge 6339 1A New Weapon In The Battle Of The Bra Bulge 6339 2New Genomic Test for Coronary Artery Disease Now Available at The Heart 26amp 3B Vascular Center of Arizona 6336 1New Genomic Test for Coronary Artery Disease Now Available at The Heart 26amp 3B Vascular Center of Arizona 6336 2New Genomic Test for Coronary Artery Disease Now Available at The Heart 26amp 3B Vascular Center of Arizona 6336 3New Genomic Test for Coronary Artery Disease Now Available at The Heart 26amp 3B Vascular Center of Arizona 6336 4
... December 10, 2007, NEW HAVEN, Conn., Dec. 6 ... that preliminary data,from its pivotal Phase II trial of ... leukemia (AML) would be presented,in a poster at the ... on Saturday, December 8, 2007., The poster presentation ...
... RDYN ) announced today that President and Chief ... and Powerful Anti-infectives,panel at the RBC Capital Markets 2007 ... am ET on Thursday, December 13, 2007 at,the Westin ... audio webcast of the panel discussion will be available ...
Other Medicine Technology:Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting 2Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting 3
(Date:12/15/2009)... About 800,000 doses have lower strength than needed for ... -- Almost 800,000 children,s doses of H1N1 swine flu ... because they have lost some potency, federal health officials ... Disease Control and Prevention, the company,s routine testing of ... 3 years found that four batches had lower than ...
(Date:12/15/2009)... not delivered ,, WASHINGTON, Dec. 15 /PRNewswire-USNewswire/ ... ensure that healthcare reform does not override the ... companies in 37 states. ,, Prostate cancer screening ... population and individuals who are identifiable as high ... have a family history of prostate cancer. The ...
(Date:12/15/2009)... MENLO PARK, Calif., Dec. 15 ... its position in the pharmaceutical and bio-tech ... (Caduceus Marketing Research). Over the past 11 ... panel, the Physicians Consulting Network (PCN®), which ... healthcare professionals covering both primary care and ...
(Date:12/15/2009)... N.Y., Dec. 15 Team In Training ... charity sports training program, has reached ... support blood cancer research and patient services. ,, ... the pre-eminent charity endurance sports training program, preparing ... half marathon, triathlon, 100-mile century cycle ride or ...
(Date:12/15/2009)... The following are the remarks by ... criminal division, at the Medicare Fraud Strike Force ... thank you for the enormous effort everyone at ... ,, Together, our Departments have and will continue ... made tremendous progress in fighting Medicare fraud in ...
Breaking Medicine News(10 mins):Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2Health News:Knowledge Networks Expands in Pharma Research With Acquisition of CMR 2Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 2Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 3
... Today Pasko Rakic , professor of neurobiology ... was named one of the inaugural recipients of the Kavli ... the cerebral cortex, the seat of human cognitive function. , ... 1901 have been given for achievements in physics, chemistry, physiology ...
... and reduced antihypertensive ... medications, ... the May,2008 (volume 8, issue 25) edition of the journal of ... the French maritime pine tree, reduces blood sugar in type II,diabetes ...
... as a Result of Increased Diagnosis Rates, According to ... ... Resources, WALTHAM, Mass., May 28 Decision Resources, ... issues, finds that the launches of emerging therapies,especially the long-acting beta2 ...
... May 28 /Xinhua-PRNewswire-FirstCall/ --,China Pharma Holdings, Inc. ... which develops, manufactures, and markets generic and ... it has entered,into a Securities Purchase Agreement ... accredited investors ("Investors") pursuant to which,China Pharma ...
... of huge rise in tumors from cell,phones and calls ... SAN FRANCISCO, May 28 Mobile phones could,kill ... a study by a,neurosurgeon and award-winning cancer expert, and ... by Dr. Vini Khurana, is the most devastating indictment ...
... hospitalized, study finds , , WEDNESDAY, May 28 (HealthDay News) ... kids: , In addition to developing asthma and respiratory ... likely to catch a whole range of severe infections, ... a new study found. , Being around smoke during ...
Other Medicine News:Health News:Kavli Prize awarded to Pasko Rakic, pioneering Yale neuroscientist 2Health News:Kavli Prize awarded to Pasko Rakic, pioneering Yale neuroscientist 3Health News:Kavli Prize awarded to Pasko Rakic, pioneering Yale neuroscientist 4Health News:Study Shows Pine Bark Naturally Reduces Cardiovascular Risk Factors in Diabetics 2Health News:Study Shows Pine Bark Naturally Reduces Cardiovascular Risk Factors in Diabetics 3Health News:Study Shows Pine Bark Naturally Reduces Cardiovascular Risk Factors in Diabetics 4Health News:Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017 2Health News:China Pharma Holdings, Inc. Enters Into Private Placement Agreements to Raise $10 Million 2Health News:China Pharma Holdings, Inc. Enters Into Private Placement Agreements to Raise $10 Million 3Health News:Mobile Phones: More Dangerous Than Smoking 2Health News:Mobile Phones: More Dangerous Than Smoking 3Health News:Secondhand Smoke Leaves Kids Prone to Severe Infections 2Health News:Secondhand Smoke Leaves Kids Prone to Severe Infections 3
The TBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of total bilirubin in serum and plasma...
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
For the quantitative in vitro determination of IgA in serum and plasma. This product is suitable for use on Hitachi 704, 705, 717, 902, 911 and 912....
Latex-enhanced immunoturbidimetric assay for the quantitative in vitro determination of C-reactive protein in serum and plasma...
Medicine Products: